Local stem cell biotech Mesoblast wins key US investor backing – The Sydney Morning Herald
The Sydney Morning Herald |
Local stem cell biotech Mesoblast wins key US investor backing
The Sydney Morning Herald Out-of-favour stem cell company Mesoblast has won significant backing for its technology from major US drug group Mallinckrodt Pharmaceutical, which has taken an option over two key products under development as well as snapping up a 5 per cent stake … |
